

Michael Fuchs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8755350/publications.pdf>

Version: 2024-02-01

34
papers

1,830
citations

623734
14
h-index

434195
31
g-index

34
all docs

34
docs citations

34
times ranked

1699
citing authors

#	ARTICLE	IF	CITATIONS
1	Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group. <i>Leukemia</i> , 2022, 36, 580-582.	7.2	12
2	9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. <i>British Journal of Haematology</i> , 2022, 196, 116-126.	2.5	9
3	Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. <i>Leukemia</i> , 2022, 36, 772-780.	7.2	6
4	Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabine and cisplatin in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD18). <i>British Journal of Haematology</i> , 2022, 196, 606-616.	2.5	4
5	Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma. <i>Infection</i> , 2022, , 1.	4.7	0
6	Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. <i>Hematological Oncology</i> , 2022, 40, 801-804.	1.7	6
7	Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2022, 197, .	2.5	0
8	Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis. <i>British Journal of Haematology</i> , 2022, 198, 401-404.	2.5	5
9	Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 107-115.	1.6	5
10	Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial. <i>Clinical Cancer Research</i> , 2021, 27, 402-407.	7.0	20
11	Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group. <i>British Journal of Haematology</i> , 2021, 193, 515-519.	2.5	5
12	Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG) TITAN. <i>British Journal of Haematology</i> , 2021, 187, 101-110.	2.5	10
13	PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e398-e409.	4.6	28
14	Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 900-906.	0.8	4
15	Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group. <i>British Journal of Haematology</i> , 2021, , .	2.5	4
16	Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data. <i>Blood</i> , 2021, 138, 879-879.	1.4	3
17	Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. <i>Leukemia</i> , 2020, 34, 953-956.	7.2	14
18	Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. <i>Blood</i> , 2020, 136, 2851-2863.	1.4	47

#	ARTICLE	IF	CITATIONS
19	Reply to H.J.A. Adams et al. Journal of Clinical Oncology, 2020, 38, 1116-1117.	1.6	0
20	Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. Journal of Clinical Oncology, 2020, 38, 2839-2848.	1.6	28
21	Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma. JAMA Oncology, 2020, 6, 872.	7.1	112
22	Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma. Journal of Clinical Oncology, 2019, 37, 3528-3537.	1.6	26
23	Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. Journal of Clinical Oncology, 2019, 37, 2835-2845.	1.6	151
24	Predictive Value of Positron Emission Tomography/Computed Tomography After ABVD-Based Chemotherapy in Early-Stage Hodgkin Lymphoma. Journal of Clinical Oncology, 2019, 37, 3324-3325.	1.6	2
25	CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2019, 20, 5826.	4.1	22
26	Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial. Blood, 2019, 134, 1547-1547.	1.4	10
27	Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. Journal of Clinical Oncology, 2018, 36, 2603-2611.	1.6	7
28	Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. Journal of Clinical Oncology, 2017, 35, 1999-2007.	1.6	108
29	Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials. Journal of Clinical Oncology, 2017, 35, 1444-1450.	1.6	32
30	Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. Journal of Clinical Oncology, 2016, 34, 4329-4337.	1.6	70
31	Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncology, The, 2016, 17, 1453-1462.	10.7	91
32	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet, The, 2015, 385, 1418-1427.	13.7	154
33	Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. New England Journal of Medicine, 2010, 363, 640-652.	27.0	824
34	Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood, 2008, 112, 367-367.	1.4	9